Loading stock data…
PTCT
$73.73+2.86 (+4.04%)
Market OpenUpdated 3:53 PM EDT
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
PTC Therapeutics, Inc. in the Healthcare sector is trading at $73.73. Wall Street consensus targets $93.93 (14 analysts), implying a +27.4% move over the next 12 months. The stock is currently 16% below its 52-week high of $87.50, remaining 6.3% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +27.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$73.73
Potential Downside
0%
Whystock Fair Value$73.73
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus14 analysts
Buy
Mean target$93.93+27.4%
Range$65.00 – $124.00
Fundamentals
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
103.47%
Volume
Today's trading volume
1.44M
Recent News
Toll Brothers upgraded, Lennar downgraded: Wall Street's top analyst calls
Toll Brothers upgraded, Lennar downgraded: Wall Street's top analyst calls
Why The PTC Therapeutics (PTCT) Story Is Shifting As Sephience Assumptions Drive New Valuations
PTC Therapeutics just saw its fair value estimate move from US$90.93 to US$91.57, a small shift that still matters if you are tracking how the story is evolving. That change sits against a split backdrop of analyst commentary, with some firms lifting ratings or targets on the back of Sephience assumptions while others are trimming or holding steady. As you read on, you will see how these different views shape the narrative you may want to follow over the coming months. Analyst Price Targets...
Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800%
This clinical-stage biotech develops targeted oral therapies for RAS/MAPK-driven cancers, with all assets currently in development.
Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More
This biotechnology firm advances targeted cancer therapies, leveraging genetic insights and strategic partnerships in oncology.
KROS Turns to Next Wave of TGF-Beta Muscle Therapies
Keros is shifting toward rinvatercept-led neuromuscular development, with phase II plans, early human signals and cash runway shaping the KROS story.